(2015). Use of demographic and pharmacy data to identify patients included within both the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN). Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.3844
. M. Saine
First name
M.
Middle name
E.
Last name
Saine
(2015). Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs. BMC Pharmacol Toxicol. http://doi.org/10.1186/s40360-015-0007-z
. (2017). Validity of diagnostic codes to identify hospitalizations for infections among patients treated with oral anti-diabetic drugs. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.4368
. (2017). Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes. BMJ Open Diabetes Res Care. http://doi.org/10.1136/bmjdrc-2017-000400
. (2017). Evaluation of methods to estimate missing days\textquoteright supply within pharmacy data of the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN). Eur J Clin Pharmacol. http://doi.org/10.1007/s00228-016-2148-4
. (2019). Concordance of hospitalizations between Clinical Practice Research Datalink and linked Hospital Episode Statistics among patients treated with oral antidiabetic therapies. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.4853
.